Editas Medicine, Inc. (EDIT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q1 '17: 682K Q2 '17: 3.1M Q3 '17: 6.3M Q4 '17: 3.7M Q1 '18: 3.9M Q2 '18: 7.4M Q3 '18: 14.5M Q4 '18: 6.1M Q1 '19: 2.1M Q2 '19: 2.3M Q3 '19: 3.8M Q4 '19: 12.3M Q1 '20: 5.7M Q2 '20: 10.7M Q3 '20: 62.8M Q4 '20: 11.4M Q1 '21: 6.5M Q2 '21: 379K Q3 '21: 6.2M Q4 '21: 12.5M Q1 '22: 6.8M Q2 '22: 6.4M Q3 '22: 42K Q4 '22: 6.5M Q1 '23: 9.9M Q2 '23: 2.9M Q3 '23: 5.3M Q4 '23: 60M Q1 '24: 1.1M Q2 '24: 513K Q3 '24: 61K Q4 '24: 30.6M Q1 '25: 4.7M Q2 '25: 3.6M Q3 '25: 7.5M Q4 '25: 24.7M Q1 '26: 2.8M Q2 '26: 11.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '15: -5.2M Q2 '15: -10.4M Q3 '15: -7.4M Q4 '15: -12.4M Q1 '16: -17.8M Q2 '16: -19.2M Q3 '16: -21.2M Q4 '16: -39M Q1 '17: -30.6M Q2 '17: -26.1M Q3 '17: -26.7M Q4 '17: -36.4M Q1 '18: -31.6M Q2 '18: -39.7M Q3 '18: -16.3M Q4 '18: -26.3M Q1 '19: -31.3M Q2 '19: -35.6M Q3 '19: -34.6M Q4 '19: -39.4M Q1 '20: -46.6M Q2 '20: -31.3M Q3 '20: 9M Q4 '20: -65.9M Q1 '21: -56.9M Q2 '21: -55.4M Q3 '21: -39.3M Q4 '21: -41.6M Q1 '22: -50.8M Q2 '22: -54.2M Q3 '22: -57.5M Q4 '22: -63.4M Q1 '23: -51M Q2 '23: -44.1M Q3 '23: -50.2M Q4 '23: -24M Q1 '24: -67M Q2 '24: -71.9M Q3 '24: -65.7M Q4 '24: -46.6M Q1 '25: -76.2M Q2 '25: -51.5M Q3 '25: -24.5M Q4 '25: -7.8M Q1 '26: -25M Q2 '26: -18.6M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '15: -5.3M Q2 '15: -47.6M Q3 '15: -7.4M Q4 '15: -12.6M Q1 '16: -17.7M Q2 '16: -19M Q3 '16: -21M Q4 '16: -39.4M Q1 '17: -31.1M Q2 '17: -26.4M Q3 '17: -26.6M Q4 '17: -36.2M Q1 '18: -30.9M Q2 '18: -38.7M Q3 '18: -15.2M Q4 '18: -25.1M Q1 '19: -29.2M Q2 '19: -33.8M Q3 '19: -32.9M Q4 '19: -37.8M Q1 '20: -37.7M Q2 '20: -23.6M Q3 '20: 7.8M Q4 '20: -62.5M Q1 '21: -56.7M Q2 '21: -55.3M Q3 '21: -39.1M Q4 '21: -41.4M Q1 '22: -50.5M Q2 '22: -53.5M Q3 '22: -55.7M Q4 '22: -60.7M Q1 '23: -49M Q2 '23: -40.3M Q3 '23: -45M Q4 '23: -18.9M Q1 '24: -62M Q2 '24: -67.6M Q3 '24: -62.1M Q4 '24: -45.4M Q1 '25: -76.1M Q2 '25: -53.2M Q3 '25: -25.1M Q4 '25: -5.6M Q1 '26: -25M Q2 '26: -18.2M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '15: -5.9M Q2 '15: 20.4M Q3 '15: -11.9M Q4 '15: -8M Q1 '16: -9.6M Q2 '16: -9.9M Q3 '16: -17M Q4 '16: -13.7M Q1 '17: 69.8M Q2 '17: -26.2M Q3 '17: -28M Q4 '17: -25.1M Q1 '18: -22.5M Q2 '18: -16.7M Q3 '18: -7.8M Q4 '18: 1.3M Q1 '19: -29M Q2 '19: -25.8M Q3 '19: -26.9M Q4 '19: 41M Q1 '20: -54.1M Q2 '20: -30.9M Q3 '20: -54.8M Q4 '20: -40.1M Q1 '21: -49.5M Q2 '21: -39M Q3 '21: -40.8M Q4 '21: -34.6M Q1 '22: -49.2M Q2 '22: -37.8M Q3 '22: -48M Q4 '22: -42.3M Q1 '23: -35.8M Q2 '23: -38.7M Q3 '23: -35.5M Q4 '23: -22.2M Q1 '24: -49.9M Q2 '24: -57.1M Q3 '24: -52.6M Q4 '24: -50.8M Q1 '25: -47.8M Q2 '25: -50.2M Q3 '25: -30.8M Q4 '25: -36.4M Q1 '26: -23.1M Q2 '26: -29.6M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '15: -6.2M Q2 '15: 19.9M Q3 '15: -12.1M Q4 '15: -8.4M Q1 '16: -10.6M Q2 '16: -11.1M Q3 '16: -17.8M Q4 '16: -14.4M Q1 '17: 69.1M Q2 '17: -26.5M Q3 '17: -28.7M Q4 '17: -25.4M Q1 '18: -23.5M Q2 '18: -18.1M Q3 '18: -8.8M Q4 '18: -88K Q1 '19: -29.7M Q2 '19: -27.3M Q3 '19: -29.1M Q4 '19: 39.3M Q1 '20: -56.2M Q2 '20: -32.7M Q3 '20: -56.6M Q4 '20: -41.5M Q1 '21: -49.6M Q2 '21: -41.7M Q3 '21: -43.1M Q4 '21: -37.4M Q1 '22: -51.5M Q2 '22: -38.5M Q3 '22: -48.6M Q4 '22: -42.9M Q1 '23: -37.6M Q2 '23: -40M Q3 '23: -35.7M Q4 '23: -23.5M Q1 '24: -51.7M Q2 '24: -60.6M Q3 '24: -55.5M Q4 '24: -51.3M Q1 '25: -47.9M Q2 '25: -50.2M Q3 '25: -31.3M Q4 '25: -36.4M Q1 '26: -23.2M Q2 '26: -29.7M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q3 '19: 49.8M Q1 '20: 54.6M Q2 '20: 55.3M Q3 '20: 62.7M Q1 '21: 66M Q2 '21: 67.9M Q3 '21: 68.2M Q1 '22: 68.5M Q2 '22: 68.6M Q3 '22: 68.7M Q1 '23: 68.9M Q2 '23: 71.4M Q3 '23: 81.6M Q1 '24: 81.9M Q2 '24: 82.3M Q3 '24: 82.5M Q1 '25: 83.1M Q2 '25: 84.4M Q3 '25: 90.1M Q1 '26: 97.9M Q2 '26: 119.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '15: -29.79 Q1 '16: -27.84 Q2 '16: -6.93 Q3 '16: -4.95 Q4 '16: -3.09 Q1 '17: -3.14 Q2 '17: -3.25 Q3 '17: -3.30 Q4 '17: -2.99 Q1 '18: -2.81 Q2 '18: -2.98 Q3 '18: -2.66 Q4 '18: -2.33 Q1 '19: -2.26 Q2 '19: -2.13 Q3 '19: -2.47 Q4 '19: -2.68 Q1 '20: -2.77 Q2 '20: -2.51 Q3 '20: -1.73 Q4 '20: -2.00 Q1 '21: -2.17 Q2 '21: -2.55 Q3 '21: -3.24 Q4 '21: -2.85 Q1 '22: -2.73 Q2 '22: -2.70 Q3 '22: -2.94 Q4 '22: -3.21 Q1 '23: -3.18 Q2 '23: -2.96 Q3 '23: -2.70 Q4 '23: -2.03 Q1 '24: -2.08 Q2 '24: -2.34 Q3 '24: -2.54 Q4 '24: -2.88 Q1 '25: -3.04 Q2 '25: -2.85 Q3 '25: -2.38 Q4 '25: -1.83 Q1 '26: -1.17 Q2 '26: -0.69 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.